Table 8.

Other properties of mTOR inhibitors.

mTOR inhibitor	Effect of mTOR inhibitors on de novo tumors
EVR	Bilbao et al. Transplant Proc. 2009; 41: 2172–6 [92]	Six recipients with de novo tumors received oncological treatment/surgery and were converted to EVR-based IS. Five were disease-free at follow-up (mean 10 ± 9 months after conversion)
EVR	Fischer et al. Am J Transplant. 2012; 12: 1855–65 [50]	Neoplasms: benign, malignant and unspecified (including cysts and polyps): 4.0% versus 8.8% (EVR versus CNI, P = NS)
SRL	Jiménez-Romero et al. Hepatogastroenterology. 2011; 58: 115–21 [62]	11 of 16 recipients who developed de novo tumors and were switched from CNI/MMF to SRL monotherapy were alive at follow-up (mean follow-up 15.7 months)
SRL	Vivarelli. Transplant Proc. 2010; 42: 2579–84 [80]	3 of 4 recipients with de novo tumors and who converted to SRL-based IS were alive and tumor-free up to 33 months after conversion
mTOR inhibitor	Effect of mTOR inhibitors on neurological symptoms
EVR	Bilbao et al. Transplant Proc. 2009; 41: 2172–6 [92]	3/3 cases of neurotoxicity resolved
EVR	Masetti et al. Am J Transplant. 2010; 10: 2252–62 [89]	Minor neurological complications: EVR: 3/52 (5.8%), CsA: 5/26 (19.2%) (P = 0.11)
SRL	Forgacs et al. Transplant Proc. 2005; 37: 1912–4 [70]	7/7 recipients showed improvement or resolution of neurological symptoms
SRL	Maramattom and WijdicksNeurology. 2004; 63: 1958–9 [64]	No neurotoxicity in 52 recipients treated with SRL from 2001–04
SRL	Morard et al. Liver Transpl. 2007; 13: 658–64 [75]	Severe CNI-associated neurological symptoms improved in 6/6 recipients who converted from CNI
SRL	Vivarelli. Transplant Proc. 2010; 42: 2579–84 [80]	Complete resolution of neurological symptoms in 14/16 recipients who converted from CNI

P values are included where available.

CNI: calcineurin inhibitor; CsA: cyclosporine A; EVR: everolimus; HCV: hepatitis C virus; IS: immunosuppression; MMF: mycophenolate mofetil; SRL: sirolimus; TAC: tacrolimus.